Sutro Biopharma (STRO) Long-Term Investments (2019 - 2022)

Sutro Biopharma (STRO) has 4 years of Long-Term Investments data on file, last reported at $20.7 million in Q1 2022.

• For the quarter ending Q1 2022, Long-Term Investments fell 72.25% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2022 stood at $20.7 million (down 72.25% YoY), and the FY2021 full-year result was $68.8 million, changed N/A from the prior year.
• Long-Term Investments eased to $20.7 million in Q1 2022, from $68.8 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $74.6 million in Q1 2021 to a low of $5.6 million in Q2 2020.
• A 4-year average of $34.3 million and a median of $20.7 million in 2022 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments soared 962.51% in 2021 and sank 72.25% in 2022, its largest moves.
• Tracing STRO's Long-Term Investments over 4 years: stood at $15.6 million in 2019, then sank by 63.8% to $5.6 million in 2020, then jumped by 1118.35% to $68.8 million in 2021, then tumbled by 69.91% to $20.7 million in 2022.
• Business Quant data shows STRO's Long-Term Investments at $20.7 million in Q1 2022, $68.8 million in Q4 2021, and $64.3 million in Q3 2021.